Abstract

Hepatocellular carcinoma (HCC) biomarkers are lacking in clinical practice. We therefore explored the pattern and composition of urinary volatile organic compounds (VOCs) in HCC patients. This was done in order to assess the feasibility of a potential non-invasive test for HCC, and to enhance our understanding of the disease. This pilot study recruited 58 participants, of whom 20 were HCC cases and 38 were non-HCC cases. The non-HCC cases included healthy individuals and patients with various stages of non-alcoholic fatty liver disease (NAFLD), including those with and without fibrosis. Urine was analysed using gas chromatography–ion mobility spectrometry (GC–IMS) and gas chromatography–time-of-flight mass spectrometry (GC–TOF-MS). GC–IMS was able to separate HCC from fibrotic cases with an area under the curve (AUC) of 0.97 (0.91–1.00), and from non-fibrotic cases with an AUC of 0.62 (0.48–0.76). For GC-TOF-MS, a subset of samples was analysed in which seven chemicals were identified and tentatively linked with HCC. These include 4-methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene (2TMS derivative), 2-butanone, 2-hexanone, benzene, 1-ethyl-2-methyl-, 3-butene-1,2-diol, 1-(2-furanyl)-, bicyclo(4.1.0)heptane, 3,7,7-trimethyl-, [1S-(1a,3β,6a)]-, and sulpiride. Urinary VOC analysis using both GC–IMS and GC-TOF-MS proved to be a feasible method of identifying HCC cases, and was also able to enhance our understanding of HCC pathogenesis.

Highlights

  • Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide [1]

  • HCC is considered a consequence of liver fibrosis/cirrhosis, with chronic viral hepatitis, alcoholic liver disease, and non-alcoholic fatty liver disease (NAFLD) being the most common underlying causes [2]

  • Test accuracy for HCC and non-HCC cases using GC–TOF-MS is provided in Supplementary Materials Table S2 and Figure S1

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide [1]. HCC is considered a consequence of liver fibrosis/cirrhosis, with chronic viral hepatitis, alcoholic liver disease, and non-alcoholic fatty liver disease (NAFLD) being the most common underlying causes [2]. Detection of HCC is usually reliant on ultrasound scan (USS) surveillance of cirrhotic patients. In these patients, the USS detection of HCC lesions varies according to the experience of the USS operator. Detection sensitivity can range from 40% to 80%. Another test that can be used for cirrhotic patients is the serum marker alpha-fetoprotein (AFP). The clinical guidelines in 2018 recommended that AFP should no longer be used in routine clinical practice [3,4]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call